Dr. Peter Johann is a Managing General Partner of NGN Capital. He joined from Boehringer Ingelheim where he was the Division Head of Corporate Development. Dr. Johann has established a worldwide network in the Biotech and Pharmaceutical Industry. His responsibilities at Boehringer Ingelheim included strategic planning, strategic projects, M&A, business development and licensing. He identified and evaluated several licensing, M&A and co-promotion deals. Prior to this Dr. Johann served at F. Hoffmann-La Roche as Global Business Leader where he led global business teams and was responsible for global marketing of oncology products as well as evaluation of pipeline products from internal and external sources. Dr. Johann joined Roche from Boehringer Mannheim where he was Head of Business Development and Marketing Molecular Medicine. Besides marketing activities Dr. Johann was involved in setting up and managing joint venture companies as member of the supervisory board. He was also responsible for licensing activities in this field. Prior to that position he had Marketing, Sales and Business Development responsibilities at Boehringer Mannheim Biochemicals, among others, for collaborations in the field of Biopharmaceuticals. Dr. Johann has additional industry experience in Business Development and Marketing of pharmaceutical products with Kaneka in Japan and with Röhm in Germany in industrial enzymes. Dr. Johann obtained his Ph.D. from the Technical University Munich. He currently serves on the Board of Directors of Micromet, Inc. (Nasdaq: MITI), Nitec Pharma AG, NaniRx Therapeutics, Vivaldi Biosciences and as a board observer at Cerapedics. He previously served on the Board of Directors of Jerini AG (FWB: J14) and as an observer on the board of Santhera Pharmaceuticals AG.

Arthur J. Higgins, was recently appointed to Blackstone Group's healthcare unit.  Previous to that he was the CEO of Bayer HealthCare and Chairman of the Bayer HealthCare Executive Committee. Mr. Higgins joined Bayer in 2004 as Chairman of the Bayer HealthCare Executive Committee and in 2006 was named Chairman of the Board of Management of Bayer HealthCare. Mr. Higgins has played a key role in driving the success of Bayer HealthCare through a combination of strong organic growth and key acquisitions, including the (euro)17 billion acquisition of the German pharmaceutical company, Schering AG, in 2006.

Mr. Higgins started his career in 1978 in England with Bristol-Myers. He subsequently worked for Sandoz (1979 to 1984) and Fisons (1984 to 1987) before moving to Abbott Laboratories in the USA (1987 to 2001), where he held various positions of increasing responsibility in the international and domestic divisions, including a two-year posting in Germany. He was appointed President of the Pharmaceutical Products Division in Chicago, Illinois, USA, in 1998. In this position, he was in charge of Abbott's pharmaceuticals business in the United States with responsibility for global pharmaceutical research and development. In 2001, he was appointed Chairman and CEO of Enzon Pharmaceuticals headquartered in Bridgewater, New Jersey, USA. In this function, he also served as Chairman of the Biotech Council of New Jersey and on the board of the U.S. National Pharmaceutical Council.

Mr. Higgins represents Bayer in the Executive Committee of the Pharmaceutical Research and Manufacturers of America (PhRMA), and is also a member of the Council of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA). From May 2007 until December 2009, Mr. Higgins was President of the European Federation of Pharmaceutical Industries and Associations (EFPIA).

Donald McCaffrey is Co-Founder, President, & CEO of Resverlogix Corp. He has over 30 years of experience in drug discovery & development, and international conference and tradeshow management across multiple industries, including biotechnology. Don has led Resverlogix through significant change and achievement from its initial days as a private company to becoming a TSX listed company, including raising over $185 million.  In addition to garnering appropriate financing for Resverlogix’s aggressive development plan, Don has strategically directed the Company in its discussions with top global pharmaceutical companies, while creating new therapeutic markets for its key technology platforms. Don’s expertise in corporate operations has attracted an international team of R&D experts to Resverlogix.  This scientific and operational expertise has pioneered RVX-208, a drug which has the potential to be first in a new class of drugs for the treatment of cardiovascular disease.  Under his guidance Resverlogix has won multiple awards including the 2008 WEF Technology Pioneer award.

Don’s career accomplishments have been recognized by the business community and peers, as he was nominated for Ernst & Young Entrepreneur of the Year twice. He is a contributor to community non-profit organizations including the United Way, Alberta Children's Hospital, Education Matters, and Calgary Urban Project Society Literacy Program.

Mr. McNeill is currently the Executive Vice President, Finance and Administration and Chief Financial Officer of IMRIS, a global leader in providing fully integrated, advanced surgical imaging solutions. Prior to joining IMRIS, Kelly was part of Resverlogix's Senior Management Team, where he made significant contributions as Chief Financial Officer.  Prior to Resverlogix, Kelly was General Manager at Haworth Ltd., a global office interiors manufacturer located in Calgary, Alberta. Haworth Ltd. is a subsidiary of Haworth Inc., a multinational office interiors manufacturer with nearly 9000 employees worldwide.  Kelly was previously Vice President, Finance at SMED International, a global office interiors manufacturer where he was part of a team that successfully defended a hostile takeover bid resulting in the sale to Haworth Inc. at a 74% premium over the share price prior to the unsolicited offer in December 1999. During his tenure at SMED International he was part of a team that raised $40 Million in equity financing in a secondary public offering on the TSX and NASDAQ. Kelly is a chartered accountant and earned a B.Comm (Hons), and M.Acc from the University of Manitoba.

From 1992 to 1997, Dr. Smith was Dean of the Faculty of Medicine at the University of Calgary.  From 1997 until 2010, he has been Editor-in-Chief of the Canadian Journal of Cardiology.  Dr. Smith’s research interests include circulatory mechanics, exercise physiology and echocardiography.  He has published more than 250 papers and book chapters and has been a contributor to many national and international organizations; he has been President of the Canadian Cardiovascular Society and the Association of Canadian Medical Colleges and Vice President of the Inter-American Society of Cardiology.  He has served on a number of public boards including the Alberta Heritage Foundation for Medical Research, the Alberta Health Professions Advisory Board, and the Premier’s Advisory Council on Health in Alberta. He founded and served as President and Director of the Peter Lougheed Medical Research Foundation, a national initiative to support excellence in health research in Canada. He is chair of the Advisory Board of the Libin Cardiovascular Institute of Alberta and from 2006 to 2010 he was appointed by the Federal Government to chair the development of a National Strategy for Cardiovascular Health and Disease.

Mr. Zuerblis was formerly Executive Vice President and Chief Financial Officer of Savient Pharmaceuticals, Inc., a position he held until May 2012. Prior to joining Savient, Mr. Zuerblis served as Chief Financial Officer and Senior Vice President at ImClone Systems from 2008 through 2009. In that role, he was responsible for the strategic planning and leadership of finance and related operations and helped lead all aspects of the sale of the company to Eli Lilly and Company. From 1994 through 2005, Mr. Zuerblis served as Chief Financial Officer of Enzon Pharmaceuticals Inc., and held the position of Corporate Controller from 1991 through 1994. Enzon developed the first three FDA approved products using PEGylation technology. Most notably during Mr. Zuerblis’ 14 year tenure, Enzon transformed from an early stage biotechnology company into a fully integrated biopharmaceutical company with five marketed products.

He began his career at KPMG, LLP in 1982 where he held management positions of increasing responsibility over a 10 year period. Mr. Zuerblis brings nearly 30 years of proven leadership expertise in building fully integrated biopharmaceutical organizations and has an established track record of managing complex commercial and research organizations, raising capital, overseeing multifaceted merger and acquisition transactions, and directing all investor and shareholder relations.

Mr. Zuerblis earned his Bachelor of Science in Accounting from Seton Hall University and is a certified public accountant in the State of New Jersey.

Mr. Zuerblis is currently a member of the Board of Directors of Resverlogix Corp. and Stemline Therapeutics.